T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Indication (Hematologic Malignancies, Solid Tumors, Others), By Region and Competition, 2020-2030F

Description

The Global T-cell Therapy Market, valued at USD 2.92 Billion in 2024, is projected to experience a CAGR of 9.9% to reach USD 5.14 Billion by 2030. T-cell therapy represents a specialized form of immunotherapy that involves modifying a patient's own T-cells to enhance their ability to identify and eliminate diseased cells, primarily cancerous ones. The market's expansion is significantly propelled by the increasing global prevalence of various cancers, continuous technological advancements in genetic engineering techniques, and substantial investments directed towards research and development for novel immunotherapeutic approaches.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.92 Billion
Market Size 2030	USD 5.14 Billion
CAGR 2025-2030	9.9%
Fastest Growing Segment	T Cell Receptor (TCR)-based
Largest Market	North America

Key Market Drivers

The escalating global burden of cancer presents a substantial and persistent demand driver for innovative therapeutic solutions, including T-cell therapy. The increasing incidence of various cancer types globally necessitates the continuous development and adoption of advanced treatment modalities that offer improved efficacy and patient outcomes, particularly for those refractory to conventional therapies. This pressing medical need directly fuels investment and research into T-cell therapies, positioning them as critical options in oncology. According to the American Cancer Society and the International Agency for Research on Cancer, April 2024, Global Cancer Statistics 2024, close to 20 million cancer cases were newly diagnosed in 2022 around the world, underscoring the vast and growing patient population requiring novel interventions.

Key Market Challenges

The inherently high cost associated with personalized T-cell therapies, driven by complex and resource-intensive manufacturing processes, presents a significant impediment to market expansion. These treatments necessitate individual modification of a patient's own T-cells, leading to high production expenses. This directly restricts widespread patient access and imposes considerable financial pressure on healthcare systems and payers globally. Consequently, the adoption rate of these innovative therapies is constrained, preventing broader market penetration despite their demonstrated clinical efficacy.

Key Market Trends

The shift towards allogeneic T-cell therapies represents a significant evolutionary step in the global T-cell therapy market, moving away from individualized autologous treatments which rely on a patient's own cells. This transition aims to address the inherent manufacturing complexities and high costs associated with personalized therapies, paving the way for more readily available, "off-the-shelf" products. These allogeneic platforms, utilizing donor cells, hold the potential to enhance scalability and accessibility, thereby broadening the eligible patient population. According to the Alliance for Regenerative Medicine, in January 2024, the sector anticipated the potential for the first United States approval of an allogeneic T-cell therapy that year.

Key Market Players

Novartis AG
Merck KGaA
Gilead Sciences Inc.
TCR2 Therapeutics Inc
Bluebird Bio Inc.
Sorrento Therapeutics Inc.
Fate Therapeutics Inc.
Pfizer Inc.
Amgen Inc
Celgene Corporation

Report Scope:

In this report, the Global T-cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

T-cell Therapy Market, By Therapy Type:

CAR T-cell Therapy
T Cell Receptor (TCR)-based
Tumor Infiltrating Lymphocytes (TIL)-based)

T-cell Therapy Market, By Indication:

Hematologic Malignancies
Solid Tumors
Others

T-cell Therapy Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global T-cell Therapy Market.

Available Customizations:

Global T-cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global T-cell Therapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based))
- 5.2.2. By Indication (Hematologic Malignancies, Solid Tumors, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America T-cell Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapy Type
- 6.2.2. By Indication
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States T-cell Therapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapy Type
    - 6.3.1.2.2. By Indication
- 6.3.2. Canada T-cell Therapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapy Type
    - 6.3.2.2.2. By Indication
- 6.3.3. Mexico T-cell Therapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapy Type
    - 6.3.3.2.2. By Indication

7. Europe T-cell Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapy Type
- 7.2.2. By Indication
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany T-cell Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapy Type
    - 7.3.1.2.2. By Indication
- 7.3.2. France T-cell Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapy Type
    - 7.3.2.2.2. By Indication
- 7.3.3. United Kingdom T-cell Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapy Type
    - 7.3.3.2.2. By Indication
- 7.3.4. Italy T-cell Therapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapy Type
    - 7.3.4.2.2. By Indication
- 7.3.5. Spain T-cell Therapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapy Type
    - 7.3.5.2.2. By Indication

8. Asia Pacific T-cell Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapy Type
- 8.2.2. By Indication
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China T-cell Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapy Type
    - 8.3.1.2.2. By Indication
- 8.3.2. India T-cell Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapy Type
    - 8.3.2.2.2. By Indication
- 8.3.3. Japan T-cell Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapy Type
    - 8.3.3.2.2. By Indication
- 8.3.4. South Korea T-cell Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapy Type
    - 8.3.4.2.2. By Indication
- 8.3.5. Australia T-cell Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapy Type
    - 8.3.5.2.2. By Indication

9. Middle East & Africa T-cell Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapy Type
- 9.2.2. By Indication
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia T-cell Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapy Type
    - 9.3.1.2.2. By Indication
- 9.3.2. UAE T-cell Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapy Type
    - 9.3.2.2.2. By Indication
- 9.3.3. South Africa T-cell Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapy Type
    - 9.3.3.2.2. By Indication

10. South America T-cell Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapy Type
- 10.2.2. By Indication
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil T-cell Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapy Type
    - 10.3.1.2.2. By Indication
- 10.3.2. Colombia T-cell Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapy Type
    - 10.3.2.2.2. By Indication
- 10.3.3. Argentina T-cell Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapy Type
    - 10.3.3.2.2. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global T-cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Gilead Sciences Inc.
15.4. TCR2 Therapeutics Inc
15.5. Bluebird Bio Inc.
15.6. Sorrento Therapeutics Inc.
15.7. Fate Therapeutics Inc.
15.8. Pfizer Inc.
15.9. Amgen Inc
15.10. Celgene Corporation